HCPCS Code J9334: Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc

HCPCS Code J9334 is used for billing efgartigimod alfa and hyaluronidase-qvfc, a medication administered subcutaneously to treat certain autoimmune conditions. It is often given to patients who experience mild weakness affecting muscles or moderate weakness affecting muscles due to neuromuscular disorders.

Yes. Efgartigimod may be prescribed for individuals with ocular muscle weakness, such as those with generalized or ocular myasthenia gravis. This weakness can interfere with eye movement, vision, and daily functioning.

Yes. In addition to myasthenia gravis, efgartigimod is sometimes used for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), also known as chronic inflammatory demyelinating polyradiculoneuropathy. Both terms describe a rare autoimmune disorder that causes progressive weakness and impaired sensory function in the legs and arms.

Coverage and reimbursement vary by payer. Providers should document the patient’s diagnosis, treatment necessity, and injection administration details clearly to support claims for J9334. Always verify prior authorization requirements with the payer.